AI assistant
Sending…
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2011
May 26, 2011
30583_dirs_2011-05-26_9532708a-1f46-496a-99fa-b77921bef613.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2011-05-25
Reporting Person: ASELAGE STEVE (EVP, Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-05-25 | Common Stock | M | 9177 | $17.33 | Acquired | 53155 | Direct |
| 2011-05-25 | Common Stock | S | 9177 | $27.00 | Disposed | 43978 | Direct |
| 2011-05-26 | Common Stock | M | 40512 | $17.33 | Acquired | 84490 | Direct |
| 2011-05-26 | Common Stock | S | 40512 | $27.0001 | Disposed | 43978 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-05-25 | Stock Option (right to buy) | $17.33 | M | 9177 | Disposed | 2017-06-06 | Common Stock (9177) | Direct |
| 2011-05-26 | Stock Option (right to buy) | $17.33 | M | 40512 | Disposed | 2017-06-06 | Common Stock (40512) | Direct |
Footnotes
F1: The price in Column 4 is a weighted average price. The prices actually received range from $27.00 to $27.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Original option vests 6/48ths on December 7, 2007 and 1/48th on the 7th of every month thereafter.
More from BIOMARIN PHARMACEUTICAL INC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Interim / Quarterly Report
2026
May 5
Report Publication Announcement
2026
May 4
M&A Activity
2026
Apr 27
M&A Activity
2026
Apr 23
Annual Report
2026
Apr 21
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19